CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of hepatocellular carcinoma.
  
  LEARNING OBJECTIVES

  • Appreciate recently updated trial results with anti-PD-L1 antibody therapy in combination with anti-VEGF therapy as adjuvant treatment for patients with HCC and a high risk of recurrence after curative resection or ablation, and avoid this approach in clinical practice.
  • Recall recently presented trial results with anti-PD-1/PD-L1 antibody therapy in combination with VEGF or multikinase inhibitors for patients with HCC receiving transarterial chemoembolization for unresectable disease, and consider the potential role of this strategy in clinical practice.
  • Consider age, performance status, degree of liver function and other clinical and logistical factors in the selection of first-line therapy for patients with unresectable or metastatic HCC.
  • Evaluate the scientific rationale for and available data with anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies for patients with HCC, and optimally incorporate available regimens into the management of this disease.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with progressive HCC.
  • Review available and emerging data with investigational agents and strategies with documented efficacy in HCC in preparation for potential availability or to enhance clinical trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Anthony El-Khoueiry, MD
  Associate Professor of Clinical Medicine
  Associate Director for Clinical Research
  Phase I Section Chief, Developmental Therapeutics
  USC Norris Comprehensive Cancer Center
  Los Angeles, California
  
  Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Eisai Inc, Elevar Therapeutics, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Qurient, Terumo Medical Corporation; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Auransa Inc, Fulgent.
  
  Richard S Finn, MD
  Professor, Department of Medicine, Division of Hematology/Oncology
  David Geffen School of Medicine at UCLA
  Director, Signal Transduction and Therapeutics Program
  Jonsson Comprehensive Cancer Center at UCLA
  Los Angeles, California
  
  Advisory Committees: CStone Pharmaceuticals, Zai Lab; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai Inc, Genentech, a member of the Roche Group, Lilly, Novartis, Merck, Pfizer Inc, Zymeworks Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai Inc, Genentech, a member of the Roche Group, Merck, Pfizer Inc, Roche Laboratories Inc; Speakers Bureaus: Genentech, a member of the Roche Group.
  
  Aiwu Ruth He, MD, PhD
  Associate Professor of Medicine
  Leader of the Gastrointestinal Cancer Program
  Lombardi Comprehensive Cancer Center
  MedStar Georgetown University Hospital
  Washington, DC
  
  Advisory Committees: Bristol Myers Squibb; Consulting Agreements: Boston Scientific Corporation; Contracted Research: AstraZeneca Pharmaceuticals LP; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Eisai Inc.
  
  Stacey Stein, MD
  Associate Professor of Medicine
  Rutgers Cancer Institute of New Jersey
  RWJBarnabus Health
  New Brunswick, New Jersey
  
  Advisory Committees: Cardinal Health, Exelixis Inc, Genentech, a member of the Roche Group, GSK, Merck, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Aethlon Medical Inc, Genentech, a member of the Roche Group, TransThera.
  
  MODERATOR
  Stephen "Fred" Divers, MD
  Chief Medical Officer
  American Oncology Network
  Hot Springs, Arkansas
  
  Advisory Committees: Daiichi Sankyo Inc; Community Oncology Panels: Caris Life Sciences, Johnson & Johnson Pharmaceuticals; Nonrelevant Financial Relationships: MiBA.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Eisai Inc.
  
  Release date: February 2025
  Expiration date: February 2026